NCT06954025View on ClinicalTrials.gov

High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
DRUG

High-intensity inpatient MDMA-assisted psychotherapy

"Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg~Psychotherapy: manualized psychotherapy"

Trial Locations (1)

2342EG

ARQ National Psychotrauma Centre / ARQ Centrum'45, Oegstgeest

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

lead

ARQ National Psychotrauma Centre

OTHER